DRG Epidemiology's coverage of cancer pain comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of cancer pain for each country as well as annualized case counts projected to the national population.
DRG Epidemiology's cancer pain forecast will answer the following questions:
Of all people with cancer pain, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with cancer pain, how many in each of the major mature pharmaceutical markets are drug-treated?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology forecasts the following cancer pain patient populations:
Total prevalent cases with breakthrough cancer pain.
Total prevalent cases with metastatic bone pain.
Total prevalent cases with neuropathic cancer pain.
Total prevalent cases with severe cancer pain
Diagnosed prevalent cases with breakthrough cancer pain.
Diagnosed prevalent cases with metastatic bone pain.
Diagnosed prevalent cases with neuropathic cancer pain.
Diagnosed prevalent cases with severe cancer pain.
Drug-treated prevalent cases of breakthrough cancer pain.
Drug-treated prevalent cases with metastatic bone pain.
Drug-treated prevalent cases with neuropathic cancer pain.
Drug-treated prevalent cases with severe cancer pain.
Non-drug-treated prevalent cases of neuropathic cancer pain.
Non-drug-treated prevalent cases with breakthrough cancer pain.
Narendra Parihar, M.P.H., is a principal epidemiologist at Clarivate. His areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. A former dentist, he earned his M.P.H. from the Tata Institute of Social Sciences in Mumbai.
